Wellstat Therapeutics Corporation is a privately-held biopharmaceutical company located in Gaithersburg, Maryland. Dedicated to the discovery, development and commercialization of innovative therapeutics that expand the frontiers of medicine, Wellstat Therapeutics Corporation is committed to improving the lives of patients with chronic and life-threatening diseases.\nWellstat Therapeutics's focus is in the following fields:\nOncology\nMetabolic Diseases\nNeurodegenerative Diseases\nNeurometabolic Diseases\nWellstat Therapeutics is developing an extensive and diverse pipeline of novel small molecule therapeutic agents. The Company owns a broad patent portfolio covering this technology and is constantly expanding its intellectual property estate. Wellstat Therapeutics' pipeline spans the stages of development from discovery through Phase III clinical trials.\nWellstat Therapeutics was founded in 1985. The Company has a highly talented management team with significant experience in drug discovery, development, and commercialization. Samuel J. Wohlstadter, a company founder and the Chief Executive Officer was also a founder of Amgen Inc., Applied Biosystems (currently a division of Applera Corporation), IGEN International Inc. (currently a subsidiary of Roche), BioVeris Corporation (currently a subsidiary of Roche), and Hyperion Catalysis International, Inc.\nWellstat Therapeutics employs dedicated scientists, business professionals and support personnel at its state-of-the-art facilities in Gaithersburg, Maryland. Wellstat Therapeutics is part of the Wellstat Group of Companies, one of the largest and leading bioscience employers in the Baltimore-Washington Metropolitan Area. The Wellstat Group of Companies has expertise in all stages of discovery research and development, including:\nChemistry\nCell and Molecular Biology\nDisease Models\nTranslational Biology\nClinical Research and Development\nProject Management\nRegulatory Quality Assurance and Control\nManufacturing\nLegal and Financial

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.

SciClone Pharmaceuticals, Inc. (SciClone ) is a global specialty pharmaceutical company. It has a product portfolio of therapies for cancer and infectious diseases. SciClone has in-licensed two products that are part of this international commercial growth strategy, DC Bead and ondansetron RapidFilm. Its DC Bead product candidate is a treatment for liver cancer, which is approved in 40 countries worldwide, including Europe and the United States. Ondansetron RapidFilm is an oral thin film formulation of ondansetron used to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy and surgery. SCV-07 is being developed for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck and for the treatment of hepatitis C virus (HCV). Thymalfasin is being developed in an ongoing clinical trial for improvement of Influenza A (H1N1) vaccination.

Celtrix is a biopharmaceutical company focused on developing novel therapeutics for the treatment of seriously debilitating, degenerative conditions primarily associated with severe trauma, chronic diseases or aging.

Part of Sio Gene Therapies, Inc., Axovant Sciences GmbH is a Swiss company located in Basel. The firm operates as a clinical-stage biopharmaceutical company which focuses on the treatment of dementia.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it is the 3rd company of its kind ever created, and has a rich tradition of innovation and commercialization. Through our efforts to identify and create breakthrough scientific research at Hebrew University, we aspire to advance commercial solutions to the most pressing global challenges facing humanity. (Contact Tamir Huberman) Some of our well-known spin-off companies include Mobileye, Orcam, Collplant, Qlight, and Briefcam. Yissum’s business partners span the globe and include companies such as Novartis, Johnson & Johnson, Merck, Intel, Google, Boston Scientific, ICL and many more. Since its inception, Yissum has registered 10,000+ patents covering 2,800+ inventions; licensed 900 technologies and produced 130+ spin-off companies.

Sotio is an international biotechnology company leading the efforts of PPF Group to build a diverse biotechnology portfolio through its own research & development, collaborations, in-licensing, investments, mergers, and acquisitions. The company is developing new medical therapies, focusing on the treatment of cancer and autoimmune diseases. The most advanced project is the SOTIO proprietary platform of active cellular immunotherapy (ACI) based on dendritic cells.

Oxeia Biopharmaceuticals, Inc. is a clinical-stage biotech company, which develops new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Its two indications are for (i) mild traumatic brain injury (?mTB?) known as concussion, and (ii) the cognitive decline, lethargy and ?brain-fog? associated with Covid-19 infection, known as Covid Longhauler syndrome (?Long Covid?). The company was founded in 2014 by Vishal Bansal, Amit Dilip Munshi & Kartik Kiran Shah and is headquartered in Boston, MA.

Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

AlgoTherapeutix SAS is a French company located in Suresnes. The firm manufactures clinical supplies. It was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix. Stéphane Thiroloix has been the CEO since then.\nThe company says this about itself: AlgoTx is a European biotech founded in 2018 to develop innovative solutions for complex pain, whose Series A funding was led by Bpifrance and Omnes Capital. ATX01 is entering Phase 2 in painful peripheral neuropathy.

Guangdong Texin Biotechnology Co., Ltd., established on 2022-03-03, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Sales of formula food for special medical purposes;Import and export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:food production;food sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Guangdong Yiyuan Lanxin Biotechnology Co., Ltd., established on 2021-04-01, Business scope includes general items:Biochemical product technology research and development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices;Sales of Class I Medical Devices;Class I Medical Device Leasing;Sales of hygiene products and single-use medical products;Manufacturing of special equipment(Manufacture of licensed professional equipment not included);Food Additive Sales;R&D and application of cell technology;Medical Research and Experimental Development;Technology intermediary service;Conference and Exhibition Services;Development of Human Gene Diagnosis and Therapy Technology;food,liquor,Manufacture of special equipment for beverage and tea production;internet sales(Except for products that require a license for sale);food sales(Only sell prepackaged food);Technology Import and Export;Import and export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Inspection and testing service;food production;beverage production;Food additive production;Health food production;Production of formula food for special medical purpose.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

ALZA Corp. is a pharmaceutical and medical systems company that develops, manufactures, and markets therapeutic systems. It provides oral, transdermal, implantable, and liposomal technologies. It is also focused on drug delivery systems with over 20 prescription pharmaceutical products. With over 10,000 employees, ALZA Corp. is a subsidiary of Johnson & Johnson. It was established in 1968 by Dr Alejandro Zaffaroni. It is based inVacaville, California.

Generon (Shanghai) Corporation Ltd. is an integrated biotech company developing therapeutic biologics for patients world-wide. Their research & development center is located in Zhang Jiang High-Tech Park, Shanghai, China. their cGMP drug manufacturing facility is located in Economic-Technological Development Area, Beijing, China. Their mission is “Innovating for Life” to develop innovative therapeutic biologics for global patients with unmet medical needs. They employ their proprietary, cutting-edge technology platforms to discover, develop and manufacture biologic therapeutics. They are focused on “best-in-class” and “first-in-class” recombinant therapeutic proteins to treat cancer, autoimmune and inflammatory diseases. They follow international quality standards for their product development and adhere to regulatory requirements of the CFDA, FDA and EMA. “Innovation and quality” are the soul of Generon in the generation of scientific data and in the processes of drug discovery, development and manufacturing.

The USC Incubator accelerates the development of USC’s top student and alumni entrepreneurs through experiential education, mentorship and community. The USC Incubator, supported by the Greif Center for Entrepreneurial Studies at USC’s Marshall School takes founders from feasibility and development work, on to customers, a tested business model, getting distribution, building a team, bootstrapping and investment preparation. They also provide access to other supporting resources, such as legal and financial assistance.

Jiangxi Xianren Bencaotang Biotechnology Co., Ltd., established on 2019-03-11, The business scope includes daily necessities,cosmetic,hygiene products,Prepackaged food sales;R & D and sales of health food(Plant Extract Sales);Chinese herbal medicine retail;Biotechnology R&D,Technology Promotion,technology transfer,technical consulting,Technical Services;Health Management Services;Nutrition and Health Consulting;Online Trade Agent;Self-operated or agent import and export of various commodities and technologies;Medical Research and Experimental Development;Bioengineering and Biological Products Development,to develop,Sales;Drug retail;Books,medical dressing,Chinese herbal drink,Chinese patent medicine,Biochemical drug sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Scancell is developing therapeutic vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.